Language:

Application of new acute kidney injury biomarkers in human randomized controlled trials

Kidney international, 2016-06, Vol.89 (6), p.1372-1379 [Peer Reviewed Journal]

2016 ;Published by Elsevier Inc. ;ISSN: 0085-2538 ;EISSN: 1523-1755 ;DOI: 10.1016/j.kint.2016.02.027 ;PMID: 27165835

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Application of new acute kidney injury biomarkers in human randomized controlled trials
Author: Parikh, Chirag R. ; Moledina, Dennis G. ; Coca, Steven G. ; Thiessen-Philbrook, Heather R. ; Garg, Amit X.
Subjects: acute kidney injury ; Acute Kidney Injury - blood ; Acute Kidney Injury - therapy ; Biomarkers - blood ; Cardiopulmonary Bypass - adverse effects ; cardiovascular disease ; Creatinine - blood ; Disease Progression ; Humans ; Interleukin-18 - blood ; Kidney Function Tests - methods ; Kidney Tubular Necrosis, Acute - blood ; Kidney Tubular Necrosis, Acute - therapy ; Lipocalin-2 - blood ; Prospective Studies ; proteomic analysis ; Randomized Controlled Trials as Topic ; Risk Factors
Is Part Of: Kidney international, 2016-06, Vol.89 (6), p.1372-1379
Description: The use of novel biomarkers of acute kidney injury (AKI) in clinical trials may help evaluate treatments for AKI. Here we explore potential applications of biomarkers in simulated clinical trials of AKI using data from the TRIBE-AKI multicenter, prospective cohort study of patients undergoing cardiac surgery. First, in a hypothetical trial of an effective therapy at the time of acute tubular necrosis to prevent kidney injury progression, use of an indirect kidney injury marker such as creatinine compared to a new direct biomarker of kidney injury reduces the proportion of true acute tubular necrosis cases enrolled. The result is a lower observed relative risk reduction with the therapy, and lower statistical power to detect a therapy effect at a given sample size. Second, the addition of AKI biomarkers (interleukin-18 and NGAL) to clinical risk factors as eligibility criteria for trial enrollment in early AKI has the potential to increase the proportion of patients who will experience AKI progression and reduce trial cost. Third, we examine AKI biomarkers as outcome measures for the purposes of identifying therapies that warrant further testing in larger, multicenter, multi-country trials. In the hypothetical trial of lower cardiopulmonary bypass time to reduce the risk of postoperative AKI, the sample size required to detect a reduction in AKI is lower if new biomarkers are used to define AKI rather than serum creatinine. Thus, incorporation of new biomarkers of AKI has the potential to increase statistical power, decrease the sample size, and lower the cost of AKI trials.
Publisher: United States: Elsevier Inc
Language: English
Identifier: ISSN: 0085-2538
EISSN: 1523-1755
DOI: 10.1016/j.kint.2016.02.027
PMID: 27165835
Source: MEDLINE
Alma/SFX Local Collection

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Application of new acute kidney injury biomarkers in human randomized controlled trials

2016 ;Published by Elsevier Inc. ;ISSN: 0085-2538 ;EISSN: 1523-1755 ;DOI: 10.1016/j.kint.2016.02.027 ;PMID: 27165835

Searching Remote Databases, Please Wait